ピナステライド: プロフェシア、ピンペシア、プロスカ、ピンカなど世界中のピナステリド系列のジェネリック医薬品情報。

ドゥータステライド: アボダート、ジェネリックアボダート情報/ ミノキシジル錠: 食べるミノキシジル/ スピロノラクトン: アルダクトン、スピロダクトン

ミノキシジル5%液:ロゲイン、リゲイン、ザンドロックス、マイノックス、スカルプメッドなどminoxidil系の情報

その他医薬品:シメチジン、ロアキュタン、スチバA（トレチノイン）、ダイアンヌ、ドロゲン錠、パントガー

先週のコメントランキング

1等 K4993236009
2等 로또맘911
3等 다두리
4等 제로니마
5等 K4983758792

6等 K4989564954
7等 K4986541807
8等 K4986307126
9等 K4992827017
10等 K4990538995

[フィナステリド] NEOSH 101 에서 긍정적인 연구결과가 나왔네요.

18年前
1,988

前の記事次の記事

FANTASTIC NEWS - Neosil Announces Positive OSH101 Phase 2a results - "increased hair growth SIGNIFIC

FANTASTIC NEWS !!!!!!!!!!!!!!!!!!!!!!!!!!!!
04 Jan 07 Neosil Announces Positive Phase 2 Data for NEOSH101, an Investigational Treatment for Androgenetic Alopecia

EMERYVILLE, CA -- (MARKET WIRE) -- January 04, 2007 -- Neosil, Inc., a privately held dermatology-focused pharmaceutical company, today announced positive Phase 2a clinical data demonstrating that its lead product, NEOSH101, increased hair growth significantly in men diagnosed with androgenetic alopecia, also known as pattern hair loss (PHL). Androgenetic alopecia or PHL, caused by a combination of genetic and hormonal factors, is noticeable in about 20 percent of the population by age 20 and increases steadily with age. By age 50 approximately half of the U.S. population will have some degree of PHL.*

"Based on the results of this study, we are quite encouraged by the increase in hair growth observed after such a short once-daily treatment regimen with NEOSH101," said Vera H. Price, MD, FRCP(C), Professor of Clinical Dermatology, Department of Dermatology, University of California, San Francisco.

In a randomized, double-blind Phase 2a clinical study, conducted in Germany, 50 men with androgenetic alopecia (Norwood/Hamilton grades III-IV) received once-daily topical treatments of NEOSH101 or placebo over two 14-day treatment periods, which were separated by a one-month drug-free interval. Hair growth was measured using an objective photographic, computer-based analysis for up to 24 weeks after initiation of therapy. Results show that NEOSH101 was safe and well tolerated. A statistically significant increase in total hair count (4.8%, p=0.04), and cumulative hair thickness (3.7%, p=0.02) were observed, with peak effects occurring eight weeks following the second treatment cycle.

"The results of this study are encouraging, particularly the finding of increased numbers of terminal hairs, those hairs that are thicker than 40 microns and desirable for scalp coverage," said Andria Langenberg, M.D., Vice President of Clinical Development at Neosil. "We plan to initiate a Phase 2b study to evaluate daily treatment with NEOSH101 for a longer treatment period in men with PHL."

About Neosil

Neosil, Inc. is a privately held dermatology-focused pharmaceutical company that was funded in November 2004 with a $32 million investment by MPM Capital and Burrill & Company, following initial incubation funding by Shalon Ventures, LP. In addition to its topical hair growth product, NEOSH101, Neosil is developing a broad-spectrum topical anti-microbial agent for acne and anti-infective use.

* Nyholt, D.R., et al.: Genetic basis for male pattern baldness, J. Investig. Dermatol. 121:1651-1564, 2003.

Media Contact: Karen Halsey 415-946-1077 Email Contact

SOURCE: Neosil

희망을 갖자구요. 내용상 2차시험에서 모발을 증가시켰다는데..빨리 머라도 나왔음 좋겠네요.